- Home
- OGI vs TLSI Comparison
OGI vs TLSI Comparison
Compare OGI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- TLSI
- Stock Information
- Founded
- OGI 2013
- TLSI 2010
- Country
- OGI Canada
- TLSI United States
- Employees
- OGI N/A
- TLSI N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- OGI Health Care
- TLSI Health Care
- Exchange
- OGI Nasdaq
- TLSI Nasdaq
- Market Cap
- OGI 176.7M
- TLSI 204.0M
- IPO Year
- OGI N/A
- TLSI N/A
- Fundamental
- Price
- OGI $1.41
- TLSI $5.07
- Analyst Decision
- OGI
- TLSI Strong Buy
- Analyst Count
- OGI 0
- TLSI 5
- Target Price
- OGI N/A
- TLSI $10.90
- AVG Volume (30 Days)
- OGI 582.2K
- TLSI 154.9K
- Earning Date
- OGI 08-12-2025
- TLSI 08-13-2025
- Dividend Yield
- OGI N/A
- TLSI N/A
- EPS Growth
- OGI N/A
- TLSI N/A
- EPS
- OGI 0.10
- TLSI N/A
- Revenue
- OGI $135,031,829.00
- TLSI $32,141,000.00
- Revenue This Year
- OGI $50.30
- TLSI $55.52
- Revenue Next Year
- OGI $16.01
- TLSI $54.76
- P/E Ratio
- OGI $16.00
- TLSI N/A
- Revenue Growth
- OGI 20.49
- TLSI 46.20
- 52 Week Low
- OGI $0.85
- TLSI $3.50
- 52 Week High
- OGI $2.08
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- OGI 58.26
- TLSI 45.72
- Support Level
- OGI $1.25
- TLSI $4.81
- Resistance Level
- OGI $1.37
- TLSI $5.63
- Average True Range (ATR)
- OGI 0.06
- TLSI 0.35
- MACD
- OGI -0.00
- TLSI -0.03
- Stochastic Oscillator
- OGI 78.26
- TLSI 30.95
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.